Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever

समान संसाधन

• Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
  द्वारा: Quartier, Pierre, और अन्य
  प्रकाशित: (2020)
• Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
  द्वारा: Wulffraat, NM, और अन्य
  प्रकाशित: (2014)
• Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
  द्वारा: Quartier, P, और अन्य
  प्रकाशित: (2014)
• PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
  द्वारा: Quartier, P, और अन्य
  प्रकाशित: (2013)
• Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
  द्वारा: Ravelli, A, और अन्य
  प्रकाशित: (2014)